BR0012050A - Derivados de purina substituìda como inibidores da adesão celular - Google Patents
Derivados de purina substituìda como inibidores da adesão celularInfo
- Publication number
- BR0012050A BR0012050A BR0012050-2A BR0012050A BR0012050A BR 0012050 A BR0012050 A BR 0012050A BR 0012050 A BR0012050 A BR 0012050A BR 0012050 A BR0012050 A BR 0012050A
- Authority
- BR
- Brazil
- Prior art keywords
- compounds
- cell
- formula
- inhibitors
- purine derivatives
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
"DERIVADOS DE PURINA SUBSTITUìDA COMO INIBIDORES DA ADESãO CELULAR". A presente invenção diz respeito a compostos da fórmula 1, em que B, D, E, G, X, Y, Z, R^ 1^, R^ 2^ e s têm os significados indicados nas reivindicações, seus sais fisiologicamente toleráveis e seus pró-medicamentos. Os compostos da fórmula 1 são compostos farmacologicamente ativos valiosos. Eles são antagonistas receptores da vitronectina e inibidores da adesão celular e são adequados para a terapia e profilaxia de enfermidades que se baseiam na interação entre os receptores da vitronectina e seus ligandos nos processos de interação célula-célula ou célula matriz ou que podem ser prevenidas, aliviadas ou curadas mediante a influência de tais interações. Por exemplo, eles podem ser aplicados para inibir a reabsorção óssea por osteoclastos e assim para tratar e prevenir a osteoporose, ou para inibir a angiogênese indesejada ou proliferação de células da musculatura lisa vascular. A invenção além disso diz respeito a processos para a preparação de compostos da fórmula (1), seu uso, em particular como ingredientes ativos em produtos farmacêuticos e composições farmacêuticas compreendendo-os.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP99112637A EP1065208A1 (en) | 1999-07-02 | 1999-07-02 | Substituted purine derivatives as inhibitors of cell adhesion |
| PCT/EP2000/005921 WO2001002399A1 (en) | 1999-07-02 | 2000-06-26 | Substituted purine derivatives as inhibitors of cell adhesion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR0012050A true BR0012050A (pt) | 2002-12-31 |
Family
ID=8238483
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR0012050-2A BR0012050A (pt) | 1999-07-02 | 2000-06-26 | Derivados de purina substituìda como inibidores da adesão celular |
Country Status (30)
| Country | Link |
|---|---|
| US (1) | US6747016B1 (pt) |
| EP (2) | EP1065208A1 (pt) |
| JP (1) | JP2003503497A (pt) |
| KR (1) | KR20020015997A (pt) |
| CN (1) | CN1171888C (pt) |
| AR (1) | AR034242A1 (pt) |
| AT (1) | ATE262528T1 (pt) |
| AU (1) | AU774382B2 (pt) |
| BG (1) | BG106229A (pt) |
| BR (1) | BR0012050A (pt) |
| CA (1) | CA2376673A1 (pt) |
| CZ (1) | CZ20014553A3 (pt) |
| DE (1) | DE60009296T2 (pt) |
| EA (1) | EA005372B1 (pt) |
| EE (1) | EE200100713A (pt) |
| ES (1) | ES2219353T3 (pt) |
| HU (1) | HUP0300183A3 (pt) |
| IL (1) | IL147245A0 (pt) |
| MX (1) | MXPA01013241A (pt) |
| MY (1) | MY122631A (pt) |
| NO (1) | NO20016403L (pt) |
| NZ (1) | NZ516095A (pt) |
| PL (1) | PL352281A1 (pt) |
| SK (1) | SK18792001A3 (pt) |
| TR (1) | TR200103858T2 (pt) |
| TW (1) | TWI229080B (pt) |
| UA (1) | UA72923C2 (pt) |
| WO (1) | WO2001002399A1 (pt) |
| YU (1) | YU89701A (pt) |
| ZA (1) | ZA200200017B (pt) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10042655A1 (de) * | 2000-08-31 | 2002-03-14 | Aventis Pharma Gmbh | Verfahren zur Herstellung von Inhibitoren der Zell-Adhäsion |
| FR2847254B1 (fr) | 2002-11-19 | 2005-01-28 | Aventis Pharma Sa | Nouveaux derives antagonistes du recepteur de la vitronectine, leur procede de preparation, leur application comme medicaments et les compositions pharmaceutiques les refermant |
| FR2870541B1 (fr) | 2004-05-18 | 2006-07-14 | Proskelia Sas | Derives de pyrimidines antigonistes du recepteur de la vitronectine |
| ES2684821T3 (es) * | 2005-12-29 | 2018-10-04 | Lexicon Pharmaceuticals, Inc. | Derivados de aminoácidos multicíclicos y métodos de su uso |
| CL2007002994A1 (es) * | 2006-10-19 | 2008-02-08 | Wyeth Corp | Compuestos derivados heterociclicos que contienen sulfamoilo, inhibidores de hsp90; composicion farmaceutica; y uso para el tratamiento del cancer, tal como cancer de mama, de colon y prostata, entre otros. |
| CN107450106A (zh) * | 2017-09-28 | 2017-12-08 | 北京小米移动软件有限公司 | 饮水安全提示方法、装置及智能水杯 |
| WO2020097400A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Imidazopyridine derivatives and aza-imidazopyridine derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020097398A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2020097396A1 (en) | 2018-11-07 | 2020-05-14 | Dana-Farber Cancer Institute, Inc. | Benzimidazole derivatives and aza-benzimidazole derivatives as janus kinase 2 inhibitors and uses thereof |
| WO2021226261A1 (en) | 2020-05-06 | 2021-11-11 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| US12043632B2 (en) | 2020-12-23 | 2024-07-23 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors |
| CA3234638A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors |
| WO2023086320A1 (en) | 2021-11-09 | 2023-05-19 | Ajax Therapeutics, Inc. | Forms and compositions of inhibitors of jak2 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69528829T2 (de) * | 1994-05-27 | 2003-08-07 | Merck & Co., Inc. | Präparate zur hemmung der durch osteoklasten vermittelten knochenresorption |
| WO1998008840A1 (en) * | 1996-08-29 | 1998-03-05 | Merck & Co., Inc. | Integrin antagonists |
| WO1998018461A1 (en) * | 1996-10-30 | 1998-05-07 | Merck & Co., Inc. | Integrin antagonists |
| DE19653646A1 (de) * | 1996-12-20 | 1998-06-25 | Hoechst Ag | Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung |
| WO1998031359A1 (en) * | 1997-01-17 | 1998-07-23 | Merck & Co., Inc. | Integrin antagonists |
| ID26219A (id) * | 1998-01-23 | 2000-12-07 | Aventis Pharma Gmbh | Turunan-turunan sulfonamida baru sebagai penghambat-penghambat resorpsi tulang dan adhesi tulang |
| AU2610099A (en) | 1998-01-28 | 1999-08-16 | Danmist Aps | Method of piezoelectrically atomising and pumping fluids and piezoelectric fluidatomising and pumping device |
-
1999
- 1999-07-02 EP EP99112637A patent/EP1065208A1/en not_active Withdrawn
-
2000
- 2000-06-26 KR KR1020017016962A patent/KR20020015997A/ko not_active Ceased
- 2000-06-26 WO PCT/EP2000/005921 patent/WO2001002399A1/en not_active Ceased
- 2000-06-26 CA CA002376673A patent/CA2376673A1/en not_active Abandoned
- 2000-06-26 EE EEP200100713A patent/EE200100713A/xx unknown
- 2000-06-26 AT AT00940406T patent/ATE262528T1/de not_active IP Right Cessation
- 2000-06-26 BR BR0012050-2A patent/BR0012050A/pt not_active IP Right Cessation
- 2000-06-26 EA EA200200121A patent/EA005372B1/ru not_active IP Right Cessation
- 2000-06-26 US US10/030,290 patent/US6747016B1/en not_active Expired - Fee Related
- 2000-06-26 EP EP00940406A patent/EP1196416B1/en not_active Expired - Lifetime
- 2000-06-26 ES ES00940406T patent/ES2219353T3/es not_active Expired - Lifetime
- 2000-06-26 CZ CZ20014553A patent/CZ20014553A3/cs unknown
- 2000-06-26 NZ NZ516095A patent/NZ516095A/en unknown
- 2000-06-26 MX MXPA01013241A patent/MXPA01013241A/es active IP Right Grant
- 2000-06-26 IL IL14724500A patent/IL147245A0/xx unknown
- 2000-06-26 PL PL00352281A patent/PL352281A1/xx not_active Application Discontinuation
- 2000-06-26 TR TR2001/03858T patent/TR200103858T2/xx unknown
- 2000-06-26 DE DE60009296T patent/DE60009296T2/de not_active Expired - Fee Related
- 2000-06-26 UA UA2002020851A patent/UA72923C2/uk unknown
- 2000-06-26 SK SK1879-2001A patent/SK18792001A3/sk unknown
- 2000-06-26 AU AU55349/00A patent/AU774382B2/en not_active Ceased
- 2000-06-26 CN CNB008121001A patent/CN1171888C/zh not_active Expired - Fee Related
- 2000-06-26 JP JP2001507836A patent/JP2003503497A/ja not_active Withdrawn
- 2000-06-26 HU HU0300183A patent/HUP0300183A3/hu unknown
- 2000-06-29 AR ARP000103314A patent/AR034242A1/es not_active Application Discontinuation
- 2000-06-29 MY MYPI20002961A patent/MY122631A/en unknown
- 2000-09-01 TW TW089117924A patent/TWI229080B/zh not_active IP Right Cessation
-
2001
- 2001-12-17 BG BG106229A patent/BG106229A/bg unknown
- 2001-12-19 YU YU89701A patent/YU89701A/sh unknown
- 2001-12-28 NO NO20016403A patent/NO20016403L/no not_active Application Discontinuation
-
2002
- 2002-01-02 ZA ZA200200017A patent/ZA200200017B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0012050A (pt) | Derivados de purina substituìda como inibidores da adesão celular | |
| BR9814308A (pt) | Derivados de acilguanidina como inibidores de ressorção óssea e como antagonistas de receptores de vitronectina | |
| BR0012129A (pt) | Derivados de naftiridina, processos para sua preparação, seu uso e composições farmacêuticas compreendendo-os | |
| BR9907735A (pt) | Derivados de sulfonamida como inibidores da reabsorção óssea e como inibidores da aderência celular | |
| BR9706387A (pt) | Derivados de purina substituìdos, processos para a sua preparação, seu emprego e composições contendo os mesmos | |
| BR0213562A (pt) | Benzimidazóis e análogos e seu uso como inibidores de cinases de proteìna | |
| NO20032905D0 (no) | Nye benzodiazepiner og beslektede heterocykliske derivater som er anvendelige som orexinreseptorantagonister | |
| BR0014760A (pt) | Derivados de purina | |
| BR0011705A (pt) | Derivados de purina | |
| BR0109200A (pt) | Compostos, processo para a preparação de compostos, composições farmacêuticas, e, processo para a fabricação das mesmas | |
| BR0214141A (pt) | Derivados de piperidina e seu uso como moduladores da atividade de receptor de quimiocina (especialmente ccr5) | |
| CA2371789A1 (en) | Novel guanidine derivatives as inhibitors of cell adhesion | |
| Ferretti et al. | Biomechanical effects of the full range of useful doses of (3-amino-1-hydroxypropylidene)-1, 1-bisphosphonate (APD) on femur diaphyses and cortical bone tissue in rats | |
| BR0208900A (pt) | Indolinas substituìdas na posição 6 e seu uso como inibidores de cinase | |
| BR0009561A (pt) | 1,4-didro indeno [1,2-c] pirazóis substituìdos como inbidores de tirosina cinase | |
| BR0015186A (pt) | N-guanidinoalquilamidas, sua preparação, seu uso, e preparações farmacêuticas compreendendo-as | |
| BR0113139A (pt) | Compostos, seus sais, formas multiméricas, pró-drogas ou metabólitos, composições farmacêuticas, método de tratamento de uma doença ou disfunção mediana através da inibição de cdk4 ou um complexo de cdk4/ciclina, método de tratamento de condição doentia em mamìferos mediada pela atividade de proteìna cinase e método de modulação ou inibição da atividade de um receptor de proteìna cinase | |
| BRPI0512420A (pt) | novos derivados de piperidina como moduladores do receptor de quimocina ccr5 | |
| Li et al. | Preadministration of incadronate disodium can prevent bone loss in rat proximal tibial metaphysis when induced by hindlimb immobilization by bandage | |
| AU2674201A (en) | Thienylalanine derivatives as inhibitors of cell adhesion | |
| MXPA02006250A (es) | Derivados de butino diol. | |
| DE60138893D1 (pt) | ||
| IT1264456B1 (it) | Derivati del 2-(benzimidazol-2-il)-1,3-diaminopropano farmacologicamente attivi. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A,8A E 9A ANUIDADE |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2008 DE 30/06/2009. |